
FY26 PROFIT GUIDANCE UPGRADE

Resonance Health Limited (ASX: RHT) (“Resonance” or “Company”) is pleased to upgrade its underlying EBITDA¹ guidance for the financial year ending 30 June 2026 (“FY26”), reflecting continued strong operational performance, improved operating leverage, and margin expansion across the business.

The Company now expects FY26 underlying EBITDA to be approximately **\$2.6 million**, equating to a **30% increase** on previous guidance of \$2.0 million, as outlined in the Company’s FY25 Full-Year Results & FY26 Guidance Investor Presentation released on 29 August 2025.

FY26 Guidance	Previous Guidance	Updated Guidance
Revenue	~\$17.0 million	~\$16.0 million
Underlying EBITDA	~\$2.0 million	~\$2.6 million
Underlying EBITDA margin	~11.8%	~16.3%

While FY26 revenue is now expected to be approximately \$16.0 million, slightly below previous guidance of \$17.0 million, this primarily reflects **timing of revenue recognition associated with a major clinical trial agreement**. The contracted revenue for this clinical trial agreement remains at approximately **\$13.8 million**, with a greater proportion of this now expected to be recognised in FY27.

Importantly, the upgraded underlying EBITDA guidance is driven by operational performance, improved cost efficiencies, and a growing contribution from higher-margin activities, rather than one-off items.

Margin Expansion

The upgraded guidance implies an FY26 underlying EBITDA margin of approximately **16.3%**, ahead of previous expectations.

This reflects the benefits of Resonance’s strategy to focus on clinical trial services, including the provision of Software-as-Medical Devices (“SaMD”) which service the clinical trial market, and other higher-margin opportunities, while maintaining disciplined cost control.

The result represents a meaningful milestone in the Company’s medium-term objective of scaling revenue toward approximately **\$30 million** and achieving an underlying EBITDA margin of approximately **25%**.

¹ Underlying EBITDA as announced on 29 August 2025

Key Drivers of the Upgrade

The upgraded underlying EBITDA guidance reflects:

- Increased contribution and operating leverage from the SaMD segment, particularly in GLP-1 driven metabolic and obesity-related imaging endpoints servicing clinical trials;
- Positive contribution from the TrialsWest investigator site network, including expanded operational capacity through opening of new clinics;
- Continued strong performance in Resonance Clinical (CRO service provision), including continued execution of major clinical trial contracts; and
- Benefits from continued automation, process and workflow improvements, and disciplined resource allocation.

Although FY26 revenue guidance has been refined to approximately \$16.0 million due to revenue recognition timing, the Company expects improved operational efficiencies and margin expansion to deliver a stronger profitability outcome than previously anticipated.

Outlook

Resonance remains well positioned to deliver sustained growth, supported by:

- A diversified business model across complementary clinical trials, SaMD, and clinical services segments;
- A strong contracted revenue base within the clinical trials pipeline;
- Continued expansion opportunities across the global clinical trial ecosystem;
- A growing contribution from higher-margin products and services; and
- Ongoing investment in automation and AI-driven technologies to enhance scalability.

The Company continues to target underlying EBITDA margin expansion over the medium-term as operating leverage increases and the business scales.

Further Information

<https://investors.resonancehealth.com>

This announcement has been authorised for release in accordance with the delegated authority of the Board of Directors of Resonance Health Limited.

For further information:

Andrew Harrison
Managing Director
E: andrewh@resonancehealth.com
P: +61 8 9286 5300

About Resonance Health

Resonance Health is an Australian healthcare technology and services company. The Company's services are used globally by clinicians in the management of human diseases and by pharmaceutical and therapeutic companies in their clinical trials. Resonance Health has gained endorsement by leading physicians worldwide for providing high quality quantitative assessments essential in managing diseases and drug development.

Resonance Health's dedication to scientific rigour and quality has enabled it to achieve regulatory clearances for a range of Software-as-Medical Devices (**SaMDs**) in the USA, Europe, UK, and Australia, and to proudly carry ISO 13485 certification for the design and manufacture of medical devices. Regulatory cleared SaMD products, some of which incorporate Artificial Intelligence (**AI**), include:

- **FerriScan®**, a core-lab product that provides an accurate assessment of liver iron concentration (**LIC**) through non-invasive MRI-based technology, for use in the assessment of individuals with iron overload conditions. Internationally recognised as the gold standard in LIC assessment.
- **FerriSmart®**, an AI-trained, non-invasive MRI-based device for the automated real-time assessment of LIC in participants, calibrated against the global gold standard, FerriScan®.
- **HepaFatScan®**, an MRI-based solution which provides a reliable non-invasive assessment of liver-fat in liver tissue for use in the assessment of individuals with confirmed or suspected fatty-liver-disease.
- **HepaFatSmart®**, an AI-trained, non-invasive device for the automated real-time multi-metric assessment of liver-fat in participants, for the assessment of individuals with confirmed or suspected fatty liver disease.
- **LiverSmart®**, an AI-trained, non-invasive MRI-based multi-parametric device combining FerriSmart® and HepaFat-AI® into a consolidated report providing accurate assessment of LIC and liver fat.
- **CardiacT2***, the most widely accepted MRI method for assessing heart iron loading. Resonance Health offers a dual analysis of FerriScan® and CardiacT2*.

The Company has a development pipeline of additional medical imaging analysis products and services, including the **MRI Liver Fibrosis Project**, aimed at accurately assessing the presence and progression of liver fibrosis utilising non-invasive MRI analysis

The Company also has a clinical trials business which both manages clinical trials in Australia and includes the site management operations of TrialsWest.

Stakeholders, including clinicians, participants, and shareholders, are encouraged to register their interest at www.resonancehealth.com and to follow Resonance Health on LinkedIn.